CD4 and metabolic dysfunction-associated steatohepatitis: Treatment of mice with a highly specific neutralizing monoclonal antibody against α4β7 inhibited α4β7+ CD4+ T cell recruitment in the colon and liver of NASH mice, attenuated hepatic and colonic mucosal inflammation, and protected the colonic epithelial barrier function to improve NASH.